Differentiating among incretin-based therapies in the management of patients with type 2 diabetes mellitus
<p>Abstract</p> <p>The glucagon-like peptide-1 receptor (GLP-1R) agonists and dipeptidyl peptidase-4 (DPP-4) inhibitors have become important options for the management of patients with type 2 diabetes mellitus. While the GLP-1R agonists and DPP-4 inhibitors act on the incretin sys...
Main Author: | Cobble Michael |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2012-03-01
|
Series: | Diabetology & Metabolic Syndrome |
Subjects: | |
Online Access: | http://www.dmsjournal.com/content/4/1/8 |
Similar Items
-
Effects of Incretin-Based Treatment on the Diastolic (Dys)Function in Patients with Uncontrolled Type 2 Diabetes Mellitus: A Prospective Study with 1-Year Follow-Up
by: Elena-Daniela Grigorescu, et al.
Published: (2023-08-01) -
Reverse phase, ion exchange, HILIC and mix-mode chromatography for the determination of metformin and evogliptin in human plasma and pharmaceutical formulations
by: Pankaj M. Kharabe, et al.
Published: (2024-08-01) -
Sitagliptin versus saxagliptin in decompensated type 2 diabetes mellitus patients
by: Antonio Asti, et al.
Published: (2016-03-01) -
SYSTEMATIC LITERATURE REVIEW ON CLINICAL EFFICACY AND SAFETY OF ALOGLIPTIN IN COMPARISON WITH VILDAGLIPTIN, LINAGLIPTIN, SAXAGLIPTIN AND SITAGLIPTIN IN ADULT PATIENTS WITH TYPE 2 DIABETES MELLITUS
by: Georgii Rubenovich Khachatryan, et al.
Published: (2015-09-01) -
Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
by: Knop FK, et al.
Published: (2010-05-01)